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Objectives. The purpose of this analysis was to determine the
influence of an additional treatment delay inherent in transfer to
an angioplasty center for primary angioplasty of patients with
acute myocardial infarction who are first admitted to hospitals
without angioplasty facilities.
Background. Several randomized trials have demonstrated the
benefits of primary angioplasty in acute myocardial infarction. In
recent years, increasing numbers of patients with myocardial
infarction, initially admitted to hospitals without angioplasty
facilities are transported to our hospital for primary angioplasty.
However, the additional delay due to the transport may have a
deleterious effect on infarct size and clinical outcome.
Methods. In a three-year period (December 1993 to November
1996), 207 consecutive patients who were transferred for primary
angioplasty were analyzed in a matched comparison with non-
transferred patients. Matching criteria were age, sex, infarct
location, presentation delay and Killip class.
Results. Patients who were transferred had an additional
median delay of 43 min. This resulted in a more extensive
enzymatic infarct size and a lower ejection fraction measured at 6
months. The rate of angioplasty success defined as TIMI grade 3
flow, and the 6-month mortality rate (7%) were comparable in
both groups.
Conclusions. The additional delay had a deleterious effect on
myocardial salvage, reflected by a larger infarct size and a lower
left ventricular function. However, the patency rate and 6-month
clinical outcome were not affected by this delay.
(J Am Coll Cardiol 1998;32:629–33)
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The time-related effect of treatment on survival and myocar-
dial salvage in patients with acute myocardial infarction (MI)
has been demonstrated in thrombolysis trials (1–6). Besides
timing of treatment, the grade of flow achieved with reperfu-
sion is important for the long-term outcome (7–10). Primary
angioplasty for patients with acute MI has been shown in
randomized trials (11–14) to be a very effective reperfusion
therapy, and high rates of complete and sustained patency have
been reported. Achieving complete reperfusion as defined by
thrombolysis in myocardial infarction (TIMI) grade 3 flow
after reperfusion is an important factor in short and long term
survival. In patients treated with thrombolytic therapy there is
an inverse relationship between time to treatment and patency
rate. This relationship is not so evident in patients treated with
primary angioplasty (15,16). A previous study in infarct pa-
tients who were admitted directly to our hospital and treated
with primary angioplasty did demonstrate differences in pa-
tency rates with increasing ischemic times, but also found
important differences in patient characteristics related to the
time from symptom onset to treatment (17). A registry study
has shown that transferring patients for primary angioplasty to
our hospital is safe and effective, and with an acceptable delay
due to transportation (18). In this analysis an attempt is made
to quantify the effect of an additional delay inherent in transfer
to an angioplasty center.
Methods
Study patients. The study was approved by the committee
on ethics and research at our institution. For this analysis we
retrospectively evaluated patients who were registered in our
infarct database. We included patients with acute MI who were
first admitted to a community hospital without angioplasty
facilities and were transferred to our hospital for primary
angioplasty. Only patients who underwent primary angioplasty
were included in the analysis. They were compared to patients
admitted directly to our hospital, who were also registered in
our database for acute MI patients. In this database, all
consecutive patients with acute MI are prospectively regis-
tered. The transfer patients and the control patients are
contemporaneous. The following definitions of the time inter-
vals were used: the first part between symptom onset and
hospital admission (for referral patients admission at the
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community hospital) is called presentation delay. The second
part is called treatment delay, and is defined as time from
hospital admission to first balloon inflation. The additional
delay due to the interhospital transport is the subject of this
analysis. Only patients who underwent primary angioplasty for
acute MI were included to allow assessment of the time to
reperfusion, defined as time to first balloon inflation. In
addition, TIMI flow grade was assessed. To study the influence
of treatment delay due to transportation, each of the trans-
ferred patients (n 5 207) was matched to one nontransferred
patient. Criteria for matching were: age, sex, infarct location,
presentation delay and Killip class. Time intervals (onset of
chest pain, presentation delay, transportation time, first bal-
loon inflation) as well as all clinical and angiographic data have
been prospectively recorded in our database. Transfer patients
were transferred from 15 community hospitals to our hospital
for primary angioplasty from December 1993 to November
1996. Our hospital serves as angioplasty center in the region
with approximately 1.5 million inhabitants. Travel distances
range from 2 to 43 miles.
Study design. Acute MI was diagnosed if a patient had
persistent symptoms of chest pain lasting more than 30 min
and had ST segment elevation of $1 mm in at least 2
contiguous leads. The indications for transfer were: electrocar-
diographic evidence of an anterior or large inferior infarction,
contraindications for thrombolytic therapy (relative or abso-
lute) or hemodynamic instability (Killip class .1). The cumu-
lative sum of ST elevation was scored on the diagnostic
electrocardiogram. The exclusion criteria were identical as
previously described (11). All transfer patients underwent
immediate coronary angiography followed by primary angio-
plasty if indicated; patients were not treated with primary
angioplasty if they had severe multivessel coronary artery
disease or involvement of the left main coronary artery that
made subsequent urgent coronary bypass grafting (CABG)
necessary. Patients with an open infarct-related vessel (IRV) in
whom no reperfusion therapy was indicated were treated
conservatively. After primary angioplasty, flow through the
IRV was scored according to the TIMI classification. The
angiograms were all read by two cardiologists blinded for
group allocation and clinical data. Primary angioplasty was
considered successful if the residual stenosis in the IRV was
less than 50% and TIMI grade 3 flow was present after the
procedure.
Enzymatic infarct size. Infarct size was determined by
measurements of enzyme concentrations with lactate dehydro-
genase as reference enzyme (LDHQ72). A two-compartment
model was used, which has been validated in studies on the
turnover of radio-labeled plasma proteins and circulating
enzymes. Cumulative enzyme release was calculated from
serial measurements up to 72 h after symptom onset. Samples
were obtained on admission and every 12 h to 72 h thereafter.
From these measurements, an area under the curve was
calculated, from at least five measurements. Further details of
this methods have been described before (11,13,19,20).
Left ventricular function. At 6-month follow-up left ven-
tricular ejection fraction (LVEF) was measured with a radio-
nuclide technique as previously described (11,13). Measure-
ments were done by the multiple-gated equilibrium method
after labeling of red blood cells with technetium 99m pertech-
netate. A gamma-camera (General Electric, Milwaukee, WI,
USA) was used. The global LVEF was calculated with the
PAGE program (version 2.3).
Clinical outcome. Follow-up information was obtained for
all patients. Hospital records of patients who visited our
outpatient clinic were reviewed. Information on transferred
patients was obtained from referral cardiologists. If necessary,
additional information was gathered by telephone contact with
general physicians or patients.
Clinical parameters. In this analysis we compared the
following clinical parameters: enzymatic infarct size
(LDHQ72), LVEF and TIMI flow after primary angioplasty was
scored. At 6-month follow-up mortality (of all causes) and
recurrent MI were evaluated in both groups. Recurrent MI was
defined as the combination of chest pain, changes in the ST-T
segment at rest, and a second increase in the creatine kinase
level to more than two times the upper limit of normal, or an
increase of more than 200 IU/liter over the previous value if
the level had not dropped below the upper limit of normal
(11). Recurrent infarction and mortality were assessed at
6-month follow-up.
Statistical methods. Time intervals are presented as medi-
ans with 25th and 75th percentiles. Data were analyzed as a
matched pairs study. The Wilcoxon signed rank test was used
to compare means of continuous variables and the chi-square
test or Fischer exact test for discrete variables. Two-sided p
values ,0.05 were considered to be significant.
Results
During a three-year period, 236 patients with acute MI were
transferred from referral hospitals. Of these, 213 patients were
treated with primary angioplasty. Eight patients with severe
multivessel coronary artery disease or involvement of the left
main coronary artery underwent urgent CABG. In another 8
patients, the IRV was open and no reperfusion therapy was
indicated. Matching criteria were available for all of the
patients who underwent primary angioplasty. No match could
be found for 6 (3%) of the transferred patients, so 207 transfer
patients were one-to-one matched to nontransferred patients.
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
IRV 5 infarct-related vessel
IU 5 international units
LDH 5 lactate dehydrogenase
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 thrombolysis in myocardial infarction
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The matching procedure resulted in an equal distribution of all
matched baseline characteristics as shown in Table 1. There
were more patients with a contraindication for thrombolysis
and with multivessel disease in the transfer patients, but these
differences were not significant. The cumulative sum of ST
elevation showed no difference between the groups. Also the
presence of other baseline characteristics such as previous
infarction, previous CABG, multivessel disease and diabetes
were equally divided. The transfer patients were slightly
younger (58 6 11 years) than patients who were enrolled in our
infarction trials in the past years, and a larger majority had an
anterior infarct location (Table 1). For the 207 matched
transfer patients, the median treatment delay was 103 min
compared to 60 min in the nontransferred patients, so the
transfer resulted in an additional delay in time to reperfusion
of 43 min (Table 2).
In-hospital clinical outcome. TIMI grade 3 flow was ob-
tained in most patients; 86% in the transfer group and in 90%
in the nontransfer group (Table 2). During the hospital period,
10 transfer patients (5%) and 7 (3%) nontransfer patients
died. Five patients died within the first 48 h, before serial
enzyme release could be determined. Cumulative enzyme
release during the first 72 h could be calculated in 145 (70%)
of the transfer patients (mean enzyme release: 1,544 IU, 6 SD
1,106 IU) and in 193 (93%) of the nontransfer patients (mean
enzyme release: 1,196 IU, 6 SD 1,004 IU). This resulted in 137
matched pairs (66%) in whom enzyme release could be
calculated and compared. For 49 (24%) patients in the transfer
group and for 16 (8%) patients in the nontransfer group, there
were inadequate data for analysis. The enzymatic infarct size
was 1,536 IU in the transferred patients, compared to 1,235 IU
in the nontransfer patients (p , 0.005) (Table 2).
Six-month follow-up. At 6 months, a total of 15 (7%)
patients in the transfer group and 12 patients in the nontrans-
fer group (6%) had died. Reinfarction had occurred in 8 (4%)
of the transfer patients and in 6 (3%) of the nontransfer
patients (Table 3). LVEF was measured at 6 months in 139
matched pairs (72%) of the survivors. Nontransfer patients
had an ejection fraction of 47% versus 43% in the transfer
patients (p 5 0.003). In 27 (13%) patients in the transfer group
and in 17 (8%) patients in the nontransfer group, a LVEF
measurement was not available; in a small number of patients
the test was performed but inconclusive due to an irregular
heart rhythm (3 patients in the transfer group and 2 in the
nontransfer group). Reasons for not performing this test were
inability to return to our hospital (e.g., travel distance) or
patient refusal.
Discussion
Treatment delay. In this study we analyzed the treatment
delay in patients who were transferred from hospitals without
angioplasty facilities to our center for primary angioplasty. In
this setting, patients who were transferred had an additional
Table 1. Baseline Characteristics
Transfer
Group
n 5 207
Nontransfer
Group
n 5 207
Age (years) (median, SD) 58 (11) 58 (10)
Male sex (%) 85 85
Anterior infarct location (%) 76 76
Heart rate (beats/min) (mean, SD) 79 (19) 76 (19)
Killip class 1–2 (%) 92 92
Killip class 3–4 (%) 8 8
Previous angina (%) 61 54
Contraindication for thrombolysis (%) 12 7
Median presentation delay (min) 90 100
(25th, 75th) (60, 145) (67, 180)
Cumulative sum of ST elevation (mm) (SD) 14 (10) 14 (11)
Previous MI (%) 11 14
Previous CABG (%) 1 0.5
Multivessel disease (%) 55 48
Diabetes (%) 5 7
CABG 5 coronary artery bypass surgery; MI, myocardial infarction.
Table 2. In-Hospital Clinical Outcome
Transfer Group
n 5 207 p Value
Nontransfer Group
n 5 207
Median treatment delay (min) 103 ,0.0001 60
(25th, 75th) (80, 130) (45, 80)
Nonfatal reinfarction 4 (2%) NS 5 (2%)
Nonfatal ischemic stroke 1 (0.5%) NS 0 (0%)
Death 10 (5%) NS 7 (3%)
TIMI grade 3 flow after PTCA 178 (86%) NS 186 (90%)
Enzymatic infarct size (LDHQ72) 1,536 IU, n 5 137 ,0.005 1,235 IU, n 5 137
NS 5 not significant; TIMI 5 Thrombolysis in myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; LDH 5 lactate dehydrogenase.
Table 3. Six-Month Clinical Outcome
Transfer Group
n 5 207
p
Value
Nontransfer Group
n 5 207
Nonfatal reinfarction 8 (4%) NS 6 (3%)
Nonfatal ischemic stroke 1 (0.5%) NS 2 (1%)
Death 15 (7%) NS 12 (6%)
Ejection fraction 43%, n 5 139 0.003 47%, n 5 139
NS 5 not significant.
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treatment delay of 43 min. Although the time delay had no
effect on the patency rate after the angioplasty procedure,
there was more extensive myocardial damage. As patency is
the major determinant of survival, this results in a comparable
6-month clinical outcome of transferred patients compared to
nontransferred patients. However, long-term survival is yet
unknown and LVEF may become more important over time.
The analysis shows that in this cohort of patients the myocar-
dial damage due to the additional delay inherent to transfer to
an angioplasty center in high-risk patients with acute MI may
be outweighed by the high rate of early, sustained and com-
plete reperfusion as a result of the primary angioplasty proce-
dure. This high rate of successful angioplasty applies to
patients with ischemic times up to 6 h, as most of the transfer
patients had short presentation delays (median 90 min) and the
additional delay caused by the transfer was limited. Few
patients with longer presentation delays were transferred, but
it may be expected that procedure success rates will be lower
after 6 h (17).
Myocardial salvage. The effects of treatment delay could
be measured in enzymatic infarct size as well as LVEF.
However, more factors may play a role in the degree of
myocardial salvage. The presence or absence of collaterals, the
size of the infarct area, history of previous infarction or
previous angina will be responsible for a wide range of
outcomes in individual patients. Nevertheless, for these patient
groups a difference in measured infarct size and LVEF was
found in relation with a median treatment delay of 43 min.
Transfer for primary angioplasty. Only a limited number
of hospitals have angioplasty facilities and most patients with
acute MI will be admitted to hospitals without these facilities.
Urgent transfer of infarct patients to angioplasty centers is an
alternative option to treatment with thrombolysis administered
at the community hospital. By evaluation of this cohort of
patients who have been transferred for primary angioplasty to
our hospital, it is demonstrated that this treatment strategy is
safe and can be done effectively. Interhospital delays are
minimized by timely referral by the physician at the referral
hospital. On arrival at the angioplasty center the patient can be
brought to the catherization laboratory immediately. Measures
to prepare the catherization laboratory can be made during the
patient transport.
Study limitations. This study population represents a se-
lected group of patients, slightly younger than the usual infarct
population and with a short presentation delay. Concerning
the high percentage of anterior infarctions the transfer
patients are a population at higher risk. This fact has
probably contributed to the differences found in enzymatic
infarct size and LVEF. In patients with nonanterior infarc-
tions, the area at risk would be smaller, and differences
expressed in infarct size and LVEF might not be measur-
able. Also the fact that the total delay before treatment for
both groups was within the period of myocardial salvage
may have contributed in the difference between the trans-
ported patients and matched controls. A bias might be
introduced by the fact that some of the clinically better
patients did not return for the LVEF test, but only in 13%
of the transported patients and in 8% of the matched
controls LVEF measurement was not available. The large
majority of patients had completed data for enzymatic
infarct size and LVEF, but in a matched comparison the
percentage of available results in patient pairs is obviously lower.
This analysis does not answer the question whether it would be
more beneficial to transfer a patient for primary angioplasty
than to treat these patients immediately with thrombolysis.
This comparison can only be made by means of a randomized
trial.
Conclusions. This analysis demonstrates that the success of
primary angioplasty in patients with acute MI is not influenced
by an additional delay due to interhospital transfer. Analysis of
time intervals showed that in our setting the additional delay is
limited and only 43 min longer in patients transferred from
community hospitals compared to patients admitted directly to
the angioplasty center. Therefore total time from symptom
onset to first balloon inflation is within a 6 h time window for
most patients. The effect of the additional treatment delay on
myocardial salvage measured in enzymatic infarct size and in
LVEF at 6 months was estimated by a matched pair analysis.
Although the additional delay was limited there was a measur-
able effect on myocardial salvage, which indicates the need to
reduce time to treatment in patients treated with primary
angioplasty. In this particular setting and infrastructure, the
transfer of patients for primary angioplasty is safe and can be
done with a limited loss of time. The high success rate in the
transfer patients is encouraging to apply this treatment strategy
for patients with high-risk features (contraindications for
thrombolysis, anterior infarct location and/or hemodynamic
instability). However, in each individual patient it should be
clear that an additional delay during the first hours of acute MI
results in more extensive myocardial damage. If transfer for
primary angioplasty is the treatment strategy of choice then the
rule “time is muscle” still holds good.
Clinical implications. The strategy to transfer patients with
acute MI admitted to a community hospital without angio-
plasty facilities to an angioplasty center is safe and effective. If
the time from symptom onset to treatment does not exceed the
period in which myocardial salvage is possible, the results of
primary angioplasty will be comparable to those obtained in
patients directly admitted to an angioplasty center. Reductions
in time to treatment can result in substantial additional
myocardial salvage.
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